Prophylactic effect of human lactoferrin against Streptococcus mutans bacteremia in lactoferrin knockout mice

Microbes and Infection

Volumn 16, Issue 9, 2014, Pages 762-767

  Velusamy, Senthil Kumar ^a   Fine, Daniel H ^a   Velliyagounder, Kabilan ^a  

^a RUTGERS SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bacteremia; Human lactoferrin; Prophylaxis; Streptococcus mutans

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTOFERRIN; MESSENGER RNA; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERLEUKIN 3; LTF PROTEIN, HUMAN; LTF PROTEIN, MOUSE; MYELOPOIETIN; NOS2 PROTEIN, HUMAN; NOS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTEREMIA; BLOOD LEVEL; CONTROLLED STUDY; HOST PARASITE INTERACTION; HUMAN; LIVER; MALE; MOUSE; NONHUMAN; PROPHYLAXIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; STREPTOCOCCUS MUTANS; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; PATHOGENICITY; STREPTOCOCCAL INFECTIONS; ULTRASTRUCTURE;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTEREMIA; C-REACTIVE PROTEIN; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1BETA; INTERLEUKIN-3; INTERLEUKIN-6; LACTOFERRIN; LIVER; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; RECOMBINANT FUSION PROTEINS; SPLEEN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS MUTANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908210881     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2014.07.009     Document Type: Article

References (43)

1. Nomura R., Hamada M., Nakano K., Nemoto H., Fujimoto K., Ooshima T. Repeated bacteraemia caused by Streptococcus mutans in a patient with Sjogren's syndrome. J Med Microbiol 2007, 56:988-992.
2. Nakano K., Hokamura K., Taniguchi N., Wada K., Kudo C., Nomura R., et al. The collagen-binding protein of Streptococcus mutans is involved in haemorrhagic stroke. Nat Commun 2011, 2:485-491.
3. Vose J.M., Smith P.W., Henry M., Colan D. Recurrent Streptococcus mutans endocarditis. Am J Med 1987, 82:630-632.
4. Fujiwara T., Nakano K., Kawaguchi M., Ooshima T., Sobue S., Kawabata S., et al. Biochemical and genetic characterization of serologically untypable Streptococcus mutans strains isolated from patients with bacteremia. Eur J Oral Sci 2001, 109:330-334.
5. Nakano K., Nomura R., Nakagawa I., Hamada S., Ooshima T. Demonstration of Streptococcus mutans with a cell wall polysaccharide specific to a new serotype, k, in the human oral cavity. J Clin Microbiol 2004, 42:198-202.
6. Kinane D.F., Riggio M.P., Walker K.F., MacKenzie D., Shearer B. Bacteraemia following periodontal procedures. J Clin Periodontol 2005, 32:708-713.
7. Lockhart P.B., Brennan M.T., Thornhill M., Michalowicz B.S., Noll J., Bahrani-Mougeot F.K., et al. Poor oral hygiene as a risk factor for infective endocarditis-related bacteremia. J Am Dent Assoc 2009, 140:1238-1244.
8. Actor J.K., Hwang S.A., Kruzel M.L. Lactoferrin as a natural immune modulator. Curr Pharm Des 2009, 15:1956-1973.
9. Clare D.A., Catignani G.L., Swaisgood H.E. Biodefense properties of milk: the role of antimicrobial proteins and peptides. Curr Pharm Des 2003, 9:1239-1255.
10. Velusamy S.K., Poojary R., Ardeshna R., Alabdulmohsen W., Fine D.H., Velliyagounder K. Protective effects of human lactoferrin during Aggregatibacter actinomycetemcomitans-induced bacteremia in lactoferrin-deficient mice. Antimicrob Agents Chemother 2014, 58:397-404.
11. Baynes R.D., Bezwoda W.R. Lactoferrin and the inflammatory response. Adv Exp Med Biol 1994, 357:133-141.
12. Damiens E., El Yazidi I., Mazurier J., Elass-Rochard E., Duthille I., Spik G., et al. Role of heparan sulphate proteoglycans in the regulation of human lactoferrin binding and activity in the MDA-MB-231 breast cancer cell line. Eur J Cell Biol 1998, 77:344-351.
13. Shau H., Kim A., Golub S.H. Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 1992, 51:343-349.
14. Suzuki Y.A., Lopez V., Lonnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005, 62:2560-2575.
15. Mincheva-Nilsson L., Hammarstrom S., Hammarstrom M.L. Activated human gamma delta T lymphocytes express functional lactoferrin receptors. Scand J Immunol 1997, 46:609-618.
16. Iyer S., Lonnerdal B. Lactoferrin, lactoferrin receptors and iron metabolism. Eur J Clin Nutr 1993, 47:232-241.
17. Arnold R.R., Russell J.E., Champion W.J., Gauthier J.J. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect Immun 1981, 32:655-660.
18. Velliyagounder K., Kaplan J.B., Furgang D., Legarda D., Diamond G., Parkin R.E., et al. One of two human lactoferrin variants exhibits increased antibacterial and transcriptional activation activities and is associated with localized juvenile periodontitis. Infect Immun 2003, 71:6141-6147.
19. Velusamy S.K., Ganeshnarayan K., Markowitz K., Schreiner H., Furgang D., Fine D.H., et al. Lactoferrin knockout mice demonstrates greater susceptibility to Aggregatibacter actinomycetemcomitans-induced periodontal disease. J Periodontol 2013, 84:1690-1701.
20. Ward P.P., Conneely O.M. Lactoferrin: role in iron homeostasis and host defense against microbial infection. Biometals 2004, 17:203-208.
21. Stinson M.W., Alder S., Kumar S. Invasion and killing of human endothelial cells by viridans group Streptococci. Infect Immun 2003, 71:2365-2372.
22. Shibata Y., Ozaki K., Seki M., Kawato T., Tanaka H., Nakano Y., et al. Analysis of loci required for determination of serotype antigenicity in Streptococcus mutans and its clinical utilization. J Clin Microbiol 2003, 41:4107-4112.
23. Kojima A., Nakano K., Wada K., Takahashi H., Katayama K., Yoneda M., et al. Infection of specific strains of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis. Sci Rep 2012, 2:1-12.
24. Gonzalez-Chavez S.A., Arevalo-Gallegos S., Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009, 33:e301-308.
25. Lassiter M.O., Newsome A.L., Sams L.D., Arnold R.R. Characterization of lactoferrin interaction with Streptococcus mutans. J Dent Res 1987, 66:480-485.
26. Soukka T., Lumikari M., Tenovuo J. Combined bactericidal effect of human lactoferrin and lysozyme against Streptococcus mutans serotype c. Microb Ecol Health Dis 1991, 4:259-264.
27. Nomura R., Nakano K., Ooshima T. Contribution of glucan-binding protein C of Streptococcus mutans to bacteremia occurrence. Arch Oral Biol 2004, 49:783-788.
28. Nakano K., Ooshima T. Serotype classification of Streptococcus mutans and its detection outside the oral cavity. Future Microbiol 2009, 4:891-902.
29. Kitten T., Munro C.L., Zollar N.Q., Lee S.P., Patel R.D. Oral streptococcal bacteremia in hospitalized patients: taxonomic identification and clinical characterization. Clin Microbiol 2012, 50:1039-1042.
30. Biswas S., Bowler I.C., Bunch C., Prendergast B., Webster D.P. Streptococcus mutans infective endocarditis complicated by vertebral discitis following dental treatment without antibiotic prophylaxis. J Med Microbiol 2010, 59:1257-1259.
31. Gauduchon V., Chalabreysse L., Etienne J., Celard M., Benito Y., Lepidi H., et al. Molecular diagnosis of infective endocarditis by PCR amplification and direct sequencing of DNA from valve tissue. J Clin Microbiol 2003, 41:763-766.
32. Gutteberg T.J., Rokke O., Andersen O., Jorgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand J Infect Dis 1989, 21:709-715.
33. Van den Berg S., Laman J.D., Boon L., Ten Kate M.T., De Knegt G.J., Verdijk R.M., et al. Distinctive cytokines as biomarkers predicting fatal outcome of severe Staphylococcus aureus bacteremia in mice. PLoS One 2013, 8:e59107.
34. Welsh K.J., Hwang S.A., Boyd S., Kruzel M.L., Hunter R.L., Actor J.K. Influence of oral lactoferrin on Mycobacterium tuberculosis induced immunopathology. Tuberc (Edinb) 2011, 91:S105-S113.
35. Zagulski T., Jarzabek Z., Zagulska A., Jaszczak M., Kochanowska I.E., Zimecki M. Lactoferrin stimulates killing and clearance of bacteria but does not prevent mortality of diabetic mice. Arch Immunol Ther Exp Warsz 2001, 49:431-438.
36. Zimecki M., Kruzel M.L. Systemic or local co-administration of lactoferrin with sensitizing dose of antigen enhances delayed type hypersensitivity in mice. Immunol Lett 2000, 74:183-188.
37. Kim J.S., Kim K.D., Na H.S., Jeong S.Y., Park H.R., Kim S., et al. Tumor necrosis factor-alpha and interleukin-1beta expression pathway induced by Streptococcus mutans in macrophage cell line RAW 264.7. Mol Oral Microbiol 2012, 27:149-159.
38. Kruzel M.L., Zimecki M. Lactoferrin and immunologic dissonance: clinical implications. Arch Immunol Ther Exp Warsz 2002, 50:399-410.
39. Hahn C.L., Best A.M., Tew J.G. Cytokine induction by Streptococcus mutans and pulpal pathogenesis. Infect Immun 2000, 68:6785-6789.
40. Soell M., Holveck F., Scholler M., Wachsmann R.D., Klein J.P. Binding of Streptococcus mutans SR protein to human monocytes: production of tumor necrosis factor, interleukin 1, and interleukin 6. Infect Immun 1994, 62:1805-1812.
41. Jiang Y., Russell T.R., Schilder H., Graves D.T. Endodontic pathogens stimulate monocyte chemoattractant protein-1 and interleukin-8 in mononuclear cells. J Endod 1998, 24:86-90.
42. Takada H., Kawabata Y., Tamura M., Matsushita K., Igarashi H., Ohkuni H., et al. Cytokine induction by extracellular products of oral viridans group Streptococci. Infect Immun 1993, 61:5252-5260.
43. Soto A., McWhinney P.H., Kibbler C.C., Cohen J. Cytokine release and mitogenic activity in the viridans streptococcal shock syndrome. Cytokine 1998, 10:370-376.